J Clin Diagn Res. 2017 Mar;11(3):BC13-BC16. doi: 10.7860/JCDR/2017/22111.9543. Epub 2017 Mar 01.

Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.

Journal of clinical and diagnostic research : JCDR

Elteza Tahjiba Jahir, Runi Devi, Bibhuti Bhushan Borthakur

PMID: 28511371 PMCID: PMC5427297 DOI: 10.7860/JCDR/2017/22111.9543

Abstract

INTRODUCTION: Breast Cancer (BC) cases are rising alarmingly all over the world and India is not an exception. This rising trend is due to an increased age at first child birth, decreased breast feeding, and the changing lifestyle mostly in urban India. With the advent of more sensitive methodologies and research works in this field, it has been suggested that Prostate Specific Antigen (PSA) plays an important role in the pathogenesis of breast cancer besides other established tumour markers.

AIM: To study the molecular forms of PSA-total and free PSA in benign and malignant tumours and to analyse their association with the tumour burden.

MATERIALS AND METHODS: The present study was conducted in collaboration with Gauhati Medical College and Hospital and Dr B Borooah Cancer Institute, Guwahati, Assam, India. Women in the age group of 18-65 years with recently diagnosed tumour (benign/malignant) in the breast were included in the study. Women taking Oral Contraceptive Pill (OCP), hormone replacement therapy, with past/present history of gynaecological/other malignancy and chronic endocrine disease like diabetes, thyroid disorders were excluded. The case group comprised of 50 female subjects with newly diagnosed Benign Breast Disease (BBD) and 50 subjects with BC, while 50 age matched healthy females without any signs and symptoms of breast discomfort were included in the control group. Laboratory tests done were Serum Total PSA (TPSA), Free PSA (FPSA), Fasting Blood Glucose (FBS), serum urea, serum creatinine and fasting lipid profile. TPSA and FPSA was measured again in both the test groups after 10-14 days of surgery/therapy.

RESULTS: A fall in postoperative value of total and free PSA in BC case group was noticed. In Grade I tumours the mean value of total PSA (1.813 ng/ml) and free PSA (1.149 ng/ml) were higher than those with Grade III tumours (TPSA-1.07 ng/ml and FPSA-1.002 ng/ml). Mean value of Fasting Blood Sugar (FBG), total cholesterol and Low Density Lipoprotein (LDL) in BC case group was higher than the control group.

CONCLUSION: From the study, we can conclude PSA as a possible new marker for diagnosis and prognosis of BC.

Keywords: Benign breast disease; Breast cancer; Prostate specific antigen

References

1. Clin Chem. 1973 May;19(5):476-82 - PubMed
2. Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):315-20 - PubMed
3. Clin Chem. 1995 Nov;41(11):1567-73 - PubMed
4. J Clin Pathol. 1960 Mar;13:156-9 - PubMed
5. Clin Cancer Res. 1998 Jun;4(6):1489-97 - PubMed
6. Cancer Res. 1994 Dec 15;54(24):6344-7 - PubMed
7. Indian J Clin Biochem. 2011 Apr;26(2):182-6 - PubMed
8. Br J Cancer. 1997;75(4):579-88 - PubMed
9. Clin Chem. 1975 Nov;21(12):1754-60 - PubMed
10. Urology. 1995 May;45(5):729-44 - PubMed
11. Clin Biochem. 1996 Jun;29(3):193-200 - PubMed
12. Clin Chem. 1980 Apr;26(5):551-4 - PubMed
13. Clin Chem. 1977 May;23(5):882-4 - PubMed
14. Breast Cancer Res Treat. 1996;40(2):171-8 - PubMed
15. Clin Biochem. 2001 Feb;34(1):71-6 - PubMed
16. Clin Chem. 1991 Sep;37(9):1618-25 - PubMed
17. J Clin Endocrinol Metab. 1995 May;80(5):1515-7 - PubMed
18. Breast Cancer Res Treat. 2000 Jan;59(1):1-14 - PubMed
19. Int J Epidemiol. 1993 Oct;22(5):772-80 - PubMed
20. Br J Cancer. 1997;76(8):1087-94 - PubMed
21. Br J Cancer. 1995 Sep;72(3):728-31 - PubMed
22. Breast Cancer Res Treat. 1994;32(3):301-10 - PubMed
23. Clin Chem. 1974 Apr;20(4):470-5 - PubMed

Publication Types

• Journal Article